HDAC6在呼吸系统疾病中的作用研究进展
|
摘要
呼吸系统疾病是目前我国常见的、多发的慢性疾病之一,已经成为影响公共健康的重大问题。呼吸道疾病与乙酰化水平有密切关系,组蛋白去乙酰化酶6 (HDAC6)作为组蛋白去乙酰化酶家族的重要成员,在慢性阻塞性肺疾病、支气管哮喘、肺动脉高压、肺纤维化、肺损伤、肺癌等呼吸系统疾病中发挥重要作用。本文主要针对HDAC6在呼吸系统疾病中的作用进行综述,并对以HDAC6为靶点的抑制剂的研究做一简要介绍。
Respiratory diseases are one of the common and frequent chronic diseases in China, and have become a major problem affecting public health. Respiratory diseases are closely related to acetylation levels. As an important member of histone deacetylase family, histone deacetylase 6(HDAC6) plays an important role in chronic obstructive pulmonary disease, bronchial asthma, pulmonary arterial hypertension, pulmonary fibrosis, lung injury, lung cancer and other respiratory diseases. Therefore, this article reviews the role of HDAC6 in respiratory diseases, and the inhibitors targeted at HDAC6 are briefly introduced.
Respiratory diseases are one of the common and frequent chronic diseases in China, and have become a major problem affecting public health. Respiratory diseases are closely related to acetylation levels. As an important member of histone deacetylase family, histone deacetylase 6(HDAC6) plays an important role in chronic obstructive pulmonary disease, bronchial asthma, pulmonary arterial hypertension, pulmonary fibrosis, lung injury, lung cancer and other respiratory diseases. Therefore, this article reviews the role of HDAC6 in respiratory diseases, and the inhibitors targeted at HDAC6 are briefly introduced.
引文
[1]顾景范.《中国居民营养与慢性病状况报告(2015)》解读[J].营养学报,2016,38(6):525-529.
[2]王甫珏,李君君.表观遗传学治疗在急性髓系白血病中的研究进展[J].海南医学,2016,27(21):3530-3533.
[3]LEE SC,MIN HY,JUNG HJ,et al.Essential role of insulin-like growth factor 2 in resistance to resistance to histone deacetylase inhibitors[J].Oncogene,2016,35(42):5515-5526.
[4]PARK EY,WOO Y,KIM SJ,et al.Anticancer effects of a new SIRTinhibitor,MHY2256,againsthuman breast cancer mcf-7 cells via regulation of MDM2-p53 binding[J].International Journal of Biological Sciences,2016,12(12):1555-1567.
[5]WOAN K V,SAHAKIAN E,SOTOMAYOR E M,et al.Modulation of antigen-presenting cells by HDAC inhibitors:implications in autoimmunity and cancer[J].Immunology and Cell Biology,2012,90(1):55-65.
[6]SETO E,YOSHIDA M.Erasers of histone acetylation:the histone deacetylase enzymes[J].Cold Spring Harbor Perspectives in Biology,2014,6(4):a018713.
[7]ASTHANA J,KAPOOR S,MOHAN R,et al.Inhibition of HDAC6deacetylase activity increases its binding with microtubules and suppresses microtubule dynamic instability in MCF-7 cells[J].Journal of Biological Chemistry,2013,288(31):22516-22526.
[8]LEE JH,MAHENDRAN A,YAO Y,et al.Development of a histone deacetylase 6 inhibitor and its biological effects[J].Proceedings of the National Academy of Sciences,2013,110(39):15704-15709.
[9]ZHENG K,JIANG Y,HE Z,et al.Cellular defence or viral assist:the dilemma of HDAC6[J].Journal of General Virology,2017,98(3):322-337.
[10]SCHULZ R,MARCHENKO N D,HOLEMBOWSKI L,et al.Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression[J].Journal of Experimental Medicine,2012,209(2):275-289.
[11]ROSENBERG SR,KALHAN R,MANNINO DM.Epidemiology of chronic obstructive pulmonary disease:prevalence,morbidity,mortality,and risk factors[C]//Seminars in respiratory and critical care medicine.Thieme Medical Publishers,2015,36(4):457-469.
[12]SHI J,LIH,YUAN C,et al.Cigarette smoke-induced acquired dysfunction of cystic fibrosis transmembrane conductance regulator in the pathogenesis of chronic obstructive pulmonary disease[J].Oxidative Medicine and Cellular Longevity,2018,2018:6567578.
[13]PROVOST K,DESAI H,SETHI S.Infectious mechanisms regulating susceptibility to acute exacerbations of COPD[M]//Smoking and Lung Inflammation.Springer,New York,NY,2013:159-176.
[14]LAM HC,CLOONAN SM,BHASHYAM AR,et al.Histone deacetylase 6-mediated selective autophagy regulates COPD-associated cilia dysfunction[J].The Journal of Clinical Investigation,2013,123(12):5212-5230.
[15]VAN DEN BOSCH T,KWIATKOWSKI M,BISCHOFF R,et al.Targeting transcription factor lysine acetylation in inflammatory airway diseases[J].Epigenomics,2017,9(7):1013-1028.
[16]任媛,苏新明,陆常玲,等.组蛋白去乙酰化酶6在慢性哮喘小鼠肺组织中的表达形态[J].中国医科大学学报,2018,47(9):788-791,802.
[17]REN Y,SU X,KONG L,et al.Therapeutic effects of histone deacetylase inhibitors in a murine asthma model[J].Inflammation Research,2016,65(12):995-1008.
[18]郑珍珍,林子英,宋泽庆,等.蛋白乙酰化和自噬在特发性肺纤维化中的研究进展[J].海南医学,2018,29(10):1423-1426.
[19]王娟.珐菲亚参胶囊辅助大容量全肺灌洗术治疗煤工尘肺的临床效果观察[J].现代医学,2016,44(2):239-241.
[20]周钱辉,彭红,颜又新,等.TGF-β1及其信号通路对话在肺纤维化中的研究进展[J].国际呼吸杂志,2018,38(4):315-320.
[21]LIU D,ZHU H,GONG L,et al.Histone deacetylases promote ERstress induced epithelial mesenchymal transition in human lung epithelial cells[J].Cellular Physiology and Biochemistry,2018,46(5):1821-1834.
[22]李红垒,徐丁洁,郭地利,等.Ac-SDKP通过调节HDAC6和HSP90抑制矽肺纤维化的机制研究[J].中国现代医学杂志,2018,28(2):1-7.
[23]NOVA Z,SKOVIEROVA H,CALKOVSKA A.Alveolar-capillary membrane-related pulmonary cells as a target in endotoxin-induced acute lung injury[J].International Journal of Molecular Sciences,2019,20(4):831.
[24]RODRIGUES SF,GRANGER DN.Blood cells and endothelial barrier function[J].Tissue Barriers,2015,3(1-2):e978720.
[25]IACONELLI J,HUANG JH,BERKOVITCH SS,et al.HDAC6 inhibitors modulate Lys49 acetylation and membrane localization ofβ-catenin in human iPSC-derived neuronal cells[J].ACS Chemical Biology,2015,10(3):883-890.
[26]JANGA H,CASSIDY L,WANG F,et al.Site-specific and endothelial-mediated dysfunction of the alveolar-capillary barrier in response to lipopolysaccharides[J].Journal of Cellular and Molecular Medicine,2018,22(2):982-998.
[27]CHATTOPADHYAY S,FENSTERL V,ZHANG Y,et al.Inhibition of viral pathogenesis and promotion of the septic shock response to bacterial infection by IRF-3 are regulated by the acetylation and phosphorylation of its coactivators[J].MBio,2013,4(2):e00636-12.
[28]YU J,MA Z,SHETTY S,et al.Selective HDAC6 inhibition prevents TNF-α-induced lung endothelial cell barrier disruption and endotoxin-induced pulmonary edema[J].American Journal of Physiology-Lung Cellular and Molecular Physiology,2016,311(1):L39-L47.
[29]SANTARPIA M,ROLFO C,PETERS GJ,et al.On the pharmacogenetics of non-small cell lung cancer treatment[J].Expert opinion on drug Metabolism&Toxicology,2016,12(3):307-317.
[30]龚道辉,闵凌峰.非小细胞肺癌顺铂耐药相关长链非编码RNA研究进展[J].国际呼吸杂志,2018,38(24):1896-1898.
[31]ANDRS M,KORABECNY J,NEPOVIMOVA E,et al.Small molecules targeting ataxia telangiectasia and Rad3-related(ATR)kinase:an emerging way to enhance existing cancer Therapy[J].Current Cancer Drug Targets,2016,16(3):200-208.
[32]YANG CJ,LIU YP,DAI HY,et al.Nuclear HDAC6 inhibits invasion by suppressing NF-κB/MMP2 and is inversely correlated with metastasis of non-small cell lung cancer[J].Oncotarget,2015,6(30):30263-30276.
[33]MATSUMOTO M,NAKAJIMA W,SEIKE M,et al.Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax-and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells[J].Biochemical and Biophysical Research Communications,2016,473(2):490-496.
[34]LEOPOLD JA,MARON BA.Molecular mechanisms of pulmonary vascular remodeling in pulmonary arterial hypertension[J].International Journal of Molecular Sciences,2016,17(5):761.
[35]BOUCHERAT O,CHABOT S,PAULIN R,et al.HDAC6:a novel histone deacetylase implicated in pulmonary arterial hypertension[J].Scientific Reports,2017,7(1):4546.
[36]YANG Z,WANG T,WANG F,et al.Discovery of selective histone deacetylase 6 inhibitors using the quinazoline as the cap for the treatment of cancer[J].Journal of Medicinal Chemistry,2015,59(4):1455-1470.
[37]KALISZCZAK M,TROUSIL S,?BERG O,et al.A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth[J].British Journal of Cancer,2013,108(2):342-350.
[38]ZHANG L,OGDEN A,ANEJA R,et al.Diverse roles of HDAC6 in viral infection:Implications for antiviral therapy[J].Pharmacology&Therapeutics,2016,164:120-125.
[39]LEE JH,MAHENDRAN A,YAO Y,et al.Development of a histone deacetylase 6 inhibitor and its biological effects[J].Proceedings of the National Academy of Sciences,2013,110(39):15704-15709.
[40]DAMASKOS C,TOMOS I,GARMPIS N,et al.Histone deacetylase inhibitors as a novel targeted therapy against non-small cell lung cancer:where are we now and what should we expect?[J].Anticancer Research,2018,38(1):37-43.
[2]王甫珏,李君君.表观遗传学治疗在急性髓系白血病中的研究进展[J].海南医学,2016,27(21):3530-3533.
[3]LEE SC,MIN HY,JUNG HJ,et al.Essential role of insulin-like growth factor 2 in resistance to resistance to histone deacetylase inhibitors[J].Oncogene,2016,35(42):5515-5526.
[4]PARK EY,WOO Y,KIM SJ,et al.Anticancer effects of a new SIRTinhibitor,MHY2256,againsthuman breast cancer mcf-7 cells via regulation of MDM2-p53 binding[J].International Journal of Biological Sciences,2016,12(12):1555-1567.
[5]WOAN K V,SAHAKIAN E,SOTOMAYOR E M,et al.Modulation of antigen-presenting cells by HDAC inhibitors:implications in autoimmunity and cancer[J].Immunology and Cell Biology,2012,90(1):55-65.
[6]SETO E,YOSHIDA M.Erasers of histone acetylation:the histone deacetylase enzymes[J].Cold Spring Harbor Perspectives in Biology,2014,6(4):a018713.
[7]ASTHANA J,KAPOOR S,MOHAN R,et al.Inhibition of HDAC6deacetylase activity increases its binding with microtubules and suppresses microtubule dynamic instability in MCF-7 cells[J].Journal of Biological Chemistry,2013,288(31):22516-22526.
[8]LEE JH,MAHENDRAN A,YAO Y,et al.Development of a histone deacetylase 6 inhibitor and its biological effects[J].Proceedings of the National Academy of Sciences,2013,110(39):15704-15709.
[9]ZHENG K,JIANG Y,HE Z,et al.Cellular defence or viral assist:the dilemma of HDAC6[J].Journal of General Virology,2017,98(3):322-337.
[10]SCHULZ R,MARCHENKO N D,HOLEMBOWSKI L,et al.Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression[J].Journal of Experimental Medicine,2012,209(2):275-289.
[11]ROSENBERG SR,KALHAN R,MANNINO DM.Epidemiology of chronic obstructive pulmonary disease:prevalence,morbidity,mortality,and risk factors[C]//Seminars in respiratory and critical care medicine.Thieme Medical Publishers,2015,36(4):457-469.
[12]SHI J,LIH,YUAN C,et al.Cigarette smoke-induced acquired dysfunction of cystic fibrosis transmembrane conductance regulator in the pathogenesis of chronic obstructive pulmonary disease[J].Oxidative Medicine and Cellular Longevity,2018,2018:6567578.
[13]PROVOST K,DESAI H,SETHI S.Infectious mechanisms regulating susceptibility to acute exacerbations of COPD[M]//Smoking and Lung Inflammation.Springer,New York,NY,2013:159-176.
[14]LAM HC,CLOONAN SM,BHASHYAM AR,et al.Histone deacetylase 6-mediated selective autophagy regulates COPD-associated cilia dysfunction[J].The Journal of Clinical Investigation,2013,123(12):5212-5230.
[15]VAN DEN BOSCH T,KWIATKOWSKI M,BISCHOFF R,et al.Targeting transcription factor lysine acetylation in inflammatory airway diseases[J].Epigenomics,2017,9(7):1013-1028.
[16]任媛,苏新明,陆常玲,等.组蛋白去乙酰化酶6在慢性哮喘小鼠肺组织中的表达形态[J].中国医科大学学报,2018,47(9):788-791,802.
[17]REN Y,SU X,KONG L,et al.Therapeutic effects of histone deacetylase inhibitors in a murine asthma model[J].Inflammation Research,2016,65(12):995-1008.
[18]郑珍珍,林子英,宋泽庆,等.蛋白乙酰化和自噬在特发性肺纤维化中的研究进展[J].海南医学,2018,29(10):1423-1426.
[19]王娟.珐菲亚参胶囊辅助大容量全肺灌洗术治疗煤工尘肺的临床效果观察[J].现代医学,2016,44(2):239-241.
[20]周钱辉,彭红,颜又新,等.TGF-β1及其信号通路对话在肺纤维化中的研究进展[J].国际呼吸杂志,2018,38(4):315-320.
[21]LIU D,ZHU H,GONG L,et al.Histone deacetylases promote ERstress induced epithelial mesenchymal transition in human lung epithelial cells[J].Cellular Physiology and Biochemistry,2018,46(5):1821-1834.
[22]李红垒,徐丁洁,郭地利,等.Ac-SDKP通过调节HDAC6和HSP90抑制矽肺纤维化的机制研究[J].中国现代医学杂志,2018,28(2):1-7.
[23]NOVA Z,SKOVIEROVA H,CALKOVSKA A.Alveolar-capillary membrane-related pulmonary cells as a target in endotoxin-induced acute lung injury[J].International Journal of Molecular Sciences,2019,20(4):831.
[24]RODRIGUES SF,GRANGER DN.Blood cells and endothelial barrier function[J].Tissue Barriers,2015,3(1-2):e978720.
[25]IACONELLI J,HUANG JH,BERKOVITCH SS,et al.HDAC6 inhibitors modulate Lys49 acetylation and membrane localization ofβ-catenin in human iPSC-derived neuronal cells[J].ACS Chemical Biology,2015,10(3):883-890.
[26]JANGA H,CASSIDY L,WANG F,et al.Site-specific and endothelial-mediated dysfunction of the alveolar-capillary barrier in response to lipopolysaccharides[J].Journal of Cellular and Molecular Medicine,2018,22(2):982-998.
[27]CHATTOPADHYAY S,FENSTERL V,ZHANG Y,et al.Inhibition of viral pathogenesis and promotion of the septic shock response to bacterial infection by IRF-3 are regulated by the acetylation and phosphorylation of its coactivators[J].MBio,2013,4(2):e00636-12.
[28]YU J,MA Z,SHETTY S,et al.Selective HDAC6 inhibition prevents TNF-α-induced lung endothelial cell barrier disruption and endotoxin-induced pulmonary edema[J].American Journal of Physiology-Lung Cellular and Molecular Physiology,2016,311(1):L39-L47.
[29]SANTARPIA M,ROLFO C,PETERS GJ,et al.On the pharmacogenetics of non-small cell lung cancer treatment[J].Expert opinion on drug Metabolism&Toxicology,2016,12(3):307-317.
[30]龚道辉,闵凌峰.非小细胞肺癌顺铂耐药相关长链非编码RNA研究进展[J].国际呼吸杂志,2018,38(24):1896-1898.
[31]ANDRS M,KORABECNY J,NEPOVIMOVA E,et al.Small molecules targeting ataxia telangiectasia and Rad3-related(ATR)kinase:an emerging way to enhance existing cancer Therapy[J].Current Cancer Drug Targets,2016,16(3):200-208.
[32]YANG CJ,LIU YP,DAI HY,et al.Nuclear HDAC6 inhibits invasion by suppressing NF-κB/MMP2 and is inversely correlated with metastasis of non-small cell lung cancer[J].Oncotarget,2015,6(30):30263-30276.
[33]MATSUMOTO M,NAKAJIMA W,SEIKE M,et al.Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax-and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells[J].Biochemical and Biophysical Research Communications,2016,473(2):490-496.
[34]LEOPOLD JA,MARON BA.Molecular mechanisms of pulmonary vascular remodeling in pulmonary arterial hypertension[J].International Journal of Molecular Sciences,2016,17(5):761.
[35]BOUCHERAT O,CHABOT S,PAULIN R,et al.HDAC6:a novel histone deacetylase implicated in pulmonary arterial hypertension[J].Scientific Reports,2017,7(1):4546.
[36]YANG Z,WANG T,WANG F,et al.Discovery of selective histone deacetylase 6 inhibitors using the quinazoline as the cap for the treatment of cancer[J].Journal of Medicinal Chemistry,2015,59(4):1455-1470.
[37]KALISZCZAK M,TROUSIL S,?BERG O,et al.A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth[J].British Journal of Cancer,2013,108(2):342-350.
[38]ZHANG L,OGDEN A,ANEJA R,et al.Diverse roles of HDAC6 in viral infection:Implications for antiviral therapy[J].Pharmacology&Therapeutics,2016,164:120-125.
[39]LEE JH,MAHENDRAN A,YAO Y,et al.Development of a histone deacetylase 6 inhibitor and its biological effects[J].Proceedings of the National Academy of Sciences,2013,110(39):15704-15709.
[40]DAMASKOS C,TOMOS I,GARMPIS N,et al.Histone deacetylase inhibitors as a novel targeted therapy against non-small cell lung cancer:where are we now and what should we expect?[J].Anticancer Research,2018,38(1):37-43.